Epacadostat Plus Pembrolizumab Shows Early Promise in Advanced RCC
Epacadostat plus pembrolizumab yielded “encouraging response outcomes” among patients with 0 or 1 prior lines of therapy for advanced renal cell carcinoma.
Current Guidelines Miss Relevant Germline Mutations in Prostate Cancer
Germline genetic testing guidelines and Gleason scores do not predict which patients with prostate cancer will test positive for pathogenic gene variants.
Significant Toxicity, Infection Risk Associated With Elo-RVD in Myeloma
In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections.
CAR T Cell/Ibrutinib Combination May Improve CLL Response Rates
Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 CAR T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia.
Carfilzomib Associated With Cardiotoxicity Risk in Multiple Myeloma
Cardiovascular adverse events are more than twice as frequent in carfilzomib arms of randomized controlled trials in multiple myeloma, according to a systematic review and meta-analysis of 24 studies.
GPS Immunization for Multiple Myeloma Is Well Tolerated
Among high-risk multiple myeloma patients, post-ASCT immunization with the Wilms tumor 1 peptide mixture galinpepimut-S is well tolerated and is associated with promising progression-free survival.
Emerging Options for CNS Lymphomas
Researchers are making much-needed progress in developing treatments for patients with three rare malignancies: recurrent and refractory primary central nervous (CNS) system lymphoma, secondary CNS lymphoma, and primary vitreoretinal lymphoma.
Does ERG Expression Predict Docetaxel Benefit in Prostate Cancer?
Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials.
Signature for Aggressive-Variant CRPC Predicts Platinum Sensitivity
A molecular signature for aggressive-variant prostate carcinoma can predict which men with castration-resistant prostate cancer will benefit from cabazitaxel with or without carboplatin.
Daratumumab Plus Standard of Care Well Tolerated in Multiple Myeloma
Adding daratumumab to standard of care is a feasible alternative to autologous stem cell transplantation with standard regimens in multiple myeloma patients.
By clicking Accept, you agree to become a member of the UBM Medica Community.